Refine
Has Fulltext
- yes (26)
Is part of the Bibliography
- yes (26)
Year of publication
- 2014 (26) (remove)
Document Type
- Journal article (17)
- Doctoral Thesis (9)
Keywords
- ADHD (2)
- ADHS (2)
- EEG (2)
- ERN (2)
- bipolar disorder (2)
- mice (2)
- 5-HT1A receptor (1)
- AAT (1)
- Alkoholkonsum (1)
- Alkoholmissbrauch (1)
- Alzheimer’s disease (1)
- Approach-Avoidance-Task (1)
- Aufmerksamkeit (1)
- Aufmerksamkeits-Defizit-Syndrom (1)
- Aufmerksamkeitslenkung (1)
- Automatische Annäherungstendenzen (1)
- Bias (1)
- Bipolar disorder (1)
- Bipolare Störung (1)
- C(-1019)G polymorphism (1)
- CNVs (1)
- COMT (1)
- COMT-Polymorphismus (1)
- Catecholmethyltransferase <Catechol-0-Methyltransferase> (1)
- Chronic disease (1)
- Cytokines (1)
- DNA (1)
- DNA methylation (1)
- DNMT3A (1)
- Depression (1)
- EBM (1)
- Early Posterior Negativity (1)
- Elektroencephalographie (1)
- Emotionsregulation (1)
- Emotionsverarbeitung (1)
- Ereigniskorrelierte Potentiale (1)
- Ereigniskorreliertes Potenzial (1)
- FMRI (1)
- FNIRS (1)
- Fehlermonitoring (1)
- Fehlerverarbeitung (1)
- Fibromyalgia syndrome (1)
- Fzd3 (1)
- GWAS (1)
- Generic questionnaire (1)
- Genexpression (1)
- Haplotyp (1)
- Haplotypanalyse (1)
- Hypertonie (1)
- Insulin (1)
- Insulin resistance (1)
- Kortikale Regulation (1)
- Late Positive Potential (1)
- MRI (1)
- Maintenance treatment (1)
- Mania (1)
- Maus (1)
- Measurement invariance (1)
- Mensch (1)
- Monopolar depression (1)
- Morbus Alzheimer (1)
- NIRS (1)
- Nah-Infrarot Reflexionsspektroskopie (1)
- OCD (1)
- Opioid receptor (1)
- P50 (1)
- PARK2 (1)
- Pe (1)
- Perinatal Asphyxia (1)
- Pharmakogenetik (1)
- Polarity index (1)
- Polymorphismus (1)
- Predominant polarity (1)
- Präfrontaler Cortex (1)
- Quetiapine (1)
- RTMS (1)
- Risikofaktoren (1)
- Riskanter Alkoholkonsum (1)
- Schizophrenia (1)
- Schizophrenie (1)
- Sensory Gating (1)
- Skin biopsy (1)
- Sozial evaluative Situation (1)
- Spontan Hypertensive Ratte (1)
- Stereology (1)
- Systematic review (1)
- Venlafaxin (1)
- Wirkmechanismus (1)
- Zerebraler Insulinmetabolismus (1)
- activation (1)
- acute mania (1)
- affective state (1)
- animal behavior (1)
- anticipation (1)
- anxiety (1)
- anxiety disorders (1)
- attentional bias (1)
- auditory cortex (1)
- autism (1)
- behavioral activation system (1)
- bipolar disorders (1)
- brain (1)
- burden (1)
- cells (1)
- cerebral artery occlusion (1)
- children (1)
- chronic heart failure (1)
- cognitive-behavioral therapy (1)
- cognitive-behavioural psychotherapy (1)
- cortisol (1)
- de-novo methylation (1)
- defensive reactivity (1)
- deficient mice (1)
- depression (1)
- disorder (1)
- dopamine (1)
- drug-addiction (1)
- early intervention (1)
- early recognition (1)
- emotional information (1)
- epigenetics (1)
- error monitoring (1)
- expression (1)
- fMRI (1)
- fear conditioning (1)
- fetal preconditioning (1)
- fumarate (1)
- fusiform gyrus (1)
- genetics (1)
- genomic response (1)
- glucocorticoid receptor (1)
- haplotypanalysis (1)
- hospitalisation (1)
- humans (1)
- illness (1)
- immediate early genes (1)
- impact (1)
- intervention study (1)
- ischemic brain injury (1)
- judgement bias (1)
- knockout mice (1)
- laboratory environment (1)
- learning (1)
- length of stay (1)
- major depression (1)
- mammalian development (1)
- management (1)
- massively multiplayer online role playing games (1)
- medial prefrontal cortex (mPFC) (1)
- memory consolidation and extinction (1)
- microarray (1)
- monetary incentive delay task (1)
- myocardial infarction (1)
- neonatal brain (1)
- neural activity (1)
- neurobiology (1)
- neuroimaging (1)
- neuropathology (1)
- neuroprotection (1)
- neuropsychology (1)
- of-the-literature (1)
- oxidative stress (1)
- panic disorder (1)
- positron-emission-tomography (1)
- posteroinferior occipitotemporal gyrus (1)
- prefrontal cortex (1)
- promoter region (1)
- protein aggregation (1)
- psychiatric-hospitalization (1)
- psychiatry (1)
- psychotic experiences (1)
- randomized-controlled trial (1)
- rat (1)
- rating scale (1)
- receptor gene polymorphism (1)
- resting-state fMRI (1)
- reward deficiency syndrome (1)
- sections (1)
- sensitivity (1)
- serotonin transporter gene (1)
- serotonin(1A) receptor (1)
- spectrum disorder (1)
- spontaneously hypertensive rats (1)
- stress (1)
- tDCS (1)
- tolerance (1)
- transcranial magnetic stimulation (1)
- transcranial magnetic stimulation (TMS) (1)
- transient global ischemia (1)
- ubiquitination (1)
- ultra-high risk (1)
- video-game (1)
- world of warcraft (1)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (26) (remove)
Obsessive compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD) are two of the most common neuropsychiatric diseases in paediatric populations. The high comorbidity of ADHD and OCD with each other, especially of ADHD in paediatric OCD, is well described. OCD and ADHD often follow a chronic course with persistent rates of at least 40–50 %. Family studies showed high heritability in ADHD and OCD, and some genetic findings showed similar variants for both disorders of the same pathogenetic mechanisms, whereas other genetic findings may differentiate between ADHD and OCD. Neuropsychological and neuroimaging studies suggest that partly similar executive functions are affected in both disorders. The deficits in the corresponding brain networks may be responsible for the perseverative, compulsive symptoms in OCD but also for the disinhibited and impulsive symptoms characterizing ADHD. This article reviews the current literature of neuroimaging, neurochemical circuitry, neuropsychological and genetic findings considering similarities as well as differences between OCD and ADHD.
Attention-deficit/hyperactivity disorder (ADHD) is a common, highly heritable neurodevelopmental disorder. Genetic loci have not yet been identified by genome-wide association studies. Rare copy number variations (CNVs), such as chromosomal deletions or duplications, have been implicated in ADHD and other neurodevelopmental disorders. To identify rare (frequency ≤1%) CNVs that increase the risk of ADHD, we performed a whole-genome CNV analysis based on 489 young ADHD patients and 1285 adult population-based controls and identified one significantly associated CNV region. In tests for a global burden of large (>500 kb) rare CNVs, we observed a nonsignificant (P=0.271) 1.126-fold enriched rate of subjects carrying at least one such CNV in the group of ADHD cases. Locus-specific tests of association were used to assess if there were more rare CNVs in cases compared with controls. Detected CNVs, which were significantly enriched in the ADHD group, were validated by quantitative (q)PCR. Findings were replicated in an independent sample of 386 young patients with ADHD and 781 young population-based healthy controls. We identified rare CNVs within the parkinson protein 2 gene (PARK2) with a significantly higher prevalence in ADHD patients than in controls \((P=2.8 × 10^{-4})\) after empirical correction for genome-wide testing). In total, the PARK2 locus (chr 6: 162 659 756-162 767 019) harboured three deletions and nine duplications in the ADHD patients and two deletions and two duplications in the controls. By qPCR analysis, we validated 11 of the 12 CNVs in ADHD patients \((P=1.2 × 10^{-3})\) after empirical correction for genome-wide testing). In the replication sample, CNVs at the PARK2 locus were found in four additional ADHD patients and one additional control \((P=4.3 × 10^{-2})\). Our results suggest that copy number variants at the PARK2 locus contribute to the genetic susceptibility of ADHD. Mutations and CNVs in PARK2 are known to be associated with Parkinson disease.
Prenatal stress-induced programming of genome-wide promoter DNA methylation in 5-HTT-deficient mice
(2014)
The serotonin transporter gene (5-HTT/SLC6A4)-linked polymorphic region has been suggested to have a modulatory role in mediating effects of early-life stress exposure on psychopathology rendering carriers of the low-expression short (s)-variant more vulnerable to environmental adversity in later life. The underlying molecular mechanisms of this gene-by-environment interaction are not well understood, but epigenetic regulation including differential DNA methylation has been postulated to have a critical role. Recently, we used a maternal restraint stress paradigm of prenatal stress (PS) in 5-HTT-deficient mice and showed that the effects on behavior and gene expression were particularly marked in the hippocampus of female 5-Htt+/- offspring. Here, we examined to which extent these effects are mediated by differential methylation of DNA. For this purpose, we performed a genome-wide hippocampal DNA methylation screening using methylated-DNA immunoprecipitation (MeDIP) on Affymetrix GeneChip Mouse Promoter 1.0 R arrays. Using hippocampal DNA from the same mice as assessed before enabled us to correlate gene-specific DNA methylation, mRNA expression and behavior. We found that 5-Htt genotype, PS and their interaction differentially affected the DNA methylation signature of numerous genes, a subset of which showed overlap with the expression profiles of the corresponding transcripts. For example, a differentially methylated region in the gene encoding myelin basic protein (Mbp) was associated with its expression in a 5-Htt-, PS- and 5-Htt × PS-dependent manner. Subsequent fine-mapping of this Mbp locus linked the methylation status of two specific CpG sites to Mbp expression and anxiety-related behavior. In conclusion, hippocampal DNA methylation patterns and expression profiles of female prenatally stressed 5-Htt+/- mice suggest that distinct molecular mechanisms, some of which are promoter methylation-dependent, contribute to the behavioral effects of the 5-Htt genotype, PS exposure and their interaction.
Background: Depression and anxiety are common and independent outcome predictors in patients with chronic heart failure (CHF). However, it is unclear whether CHF causes depression. Thus, we investigated whether mice develop anxiety- and depression-like behavior after induction of ischemic CHF by myocardial infarction (MI).
Methods and Results: In order to assess depression-like behavior, anhedonia was investigated by repeatedly testing sucrose preference for 8 weeks after coronary artery ligation or sham operation. Mice with large MI and increased left ventricular dimensions on echocardiography (termed CHF mice) showed reduced preference for sucrose, indicating depression-like behavior. 6 weeks after MI, mice were tested for exploratory activity, anxiety-like behavior and cognitive function using the elevated plus maze (EPM), light-dark box (LDB), open field (OF), and object recognition (OR) tests. In the EPM and OF, CHF mice exhibited diminished exploratory behavior and motivation despite similar movement capability. In the OR, CHF mice had reduced preference for novelty and impaired short-term memory. On histology, CHF mice had unaltered overall cerebral morphology. However, analysis of gene expression by RNA-sequencing in prefrontal cortical, hippocampal, and left ventricular tissue revealed changes in genes related to inflammation and cofactors of neuronal signal transduction in CHF mice, with Nr4a1 being dysregulated both in prefrontal cortex and myocardium after MI.
Conclusions: After induction of ischemic CHF, mice exhibited anhedonic behavior, decreased exploratory activity and interest in novelty, and cognitive impairment. Thus, ischemic CHF leads to distinct behavioral changes in mice analogous to symptoms observed in humans with CHF and comorbid depression.
Depressive Erkrankungen verursachen sowohl das persönliche Leid der erkrankten Individuen als auch volkswirtschaftlichen Schaden durch krankheitsbedingten Arbeitsausfall und Belastung der Gesundheitsversorgungssysteme. Therapeutische Konzepte wie die Anwendung pharmakotherapeutischer Intervention sind in unterschiedlichem Maß von Erfolg gekrönt.
Zahlreiche somatische Faktoren wurden mit der Ätiologie depressiver Störungen in Verbindung gebracht. Die primär verfolgten pharmakologischen Ansätze basieren nach wie vor auf Erkenntnissen aus der Mitte des vergangenen Jahrhunderts. In erster Linie setzt die Pharmakotherapie Substanzen ein, die die Wiederaufnahme monoaminerger Neurotransmitter (Serotonin, Noradrenalin, zum Teil auch Dopamin) aus dem synaptischen Spalt inhibieren und nach einer allerdings meist mehrwöchigen, regelmäßigen Einnahme des Präparates zu einem Rückgang der depressiven Symptomatik führen. Andererseits kann jedoch bei zahlreichen Erkrankten auch nach fortgesetzter Therapie mit verschiedenen Behandlungsansätzen keine Remission verzeichnet werden und es stellt sich die Frage nach der Ursache dieser Diskrepanz.
Im Fokus der vorliegenden Arbeit stand der als Antidepressivum eingesetzte selektive Serotonin- / Noradrenalin-Wiederaufnahme-Inhibitor Venlafaxin. Durch Blockade des präsynaptischen Serotonin- und Noradrenalin-Transporters führt Venlafaxin initial zu einer intensivierten Neurotransmission. Die Zielstrukturen von Venlafaxin sind der präsynaptische Serotonin- und der Noradrenalin-Transporter, wobei aufgrund unterschiedlicher Affinität eine geringe Dosis beziehungsweise Konzentration als rein serotonerg betrachtet wird und bei einer hohen Dosis beziehungsweise Konzentration sowohl die Wiederaufnahme von Serotonin als auch Noradrenalin inhibiert wird.
Es wurden in dieser Arbeit zwei Ziele verfolgt. Im ersten Teil wurde mittels Gen-expressionsuntersuchungen nach potentiellen Effektoren von Venlafaxin gesucht, um prinzipielle Mechanismen der antidepressiven Wirkung zu identifizieren und auf ihrer Basis die Entwicklung spezifischerer Intervention zu ermöglichen.
Der zweite Teil beinhaltet eine pharmakogenetische Untersuchung am Menschen. Ziel war zu evaluieren, inwieweit die Expressionsaktivität von SLC6A2 und SLC6A4 und damit die präsynaptische Transportkapazität in Kombination mit der Serumkonzentration aktiver Substanz als Prädiktor des therapeutischen Effektes dienen kann. Die Kenntnis dieser Zusammenhänge würde bei Vorliegen eines bestimmten Genotyps eine gezieltere Titration der individuell benötigten Konzentration ermöglichen und könnte die Effektivität der Therapie steigern.
Für die Genexpressionsuntersuchungen erhielten DBA/2-Mäuse über einen Zeitraum von 30 Tagen Venlafaxin in verschiedenen Dosierungen über das Trinkwasser. Anschließend wurden die Hippokampi der Tiere mittels genomweiter Microarray-Analyse hypothesenfrei auf zwischen den Dosisgruppen differentiell exprimierte Gene hin untersucht. Der Hippokampus wird als zentrales Element der Steuerung, Ausbildung und Veränderung von Verhaltensmustern gesehen. Signifikant differentiell exprimierte Gene, die in vorherigen Studien mit depressiver Erkrankung beziehungsweise einem Effekt psychiatrischer Medikation assoziiert worden waren, wurden mittels qRT-PCR-Analyse validiert. Im Anschluss an die Analyse im Tier wurden als differentiell exprimiert bestätigte Gene per qRT-PCR analog in humanen Leukozyten untersucht. Die Blutproben waren in einem klinisch-naturalistischen Design während der ersten und der fünften Woche einer Venlafaxin-Pharmakotherapie von Patienten der Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Universitätsklinikums Würzburg gewonnen worden, das heißt vor und nach potentiellem Eintreten der antidepressiven Wirkung. Trotz der unterschiedlichen Herkunft der analysierten Gewebe könnten auf diesem Weg Hinweise auf Vorgänge im menschlichen Gehirn gefunden werden, wie in vergleichenden post mortem Untersuchungen zwischen peripherem und zentralem humanem Material erkannt worden war.
Die in der Tierstudie identifizierten Gene kodieren für Transkriptionsfaktoren sowie Proteine die als Teil von second messenger-Kaskaden bekannt sind. Von statistischer Signifikanz erwies sich in der Analyse der humanen Leukozyten die Expressionsreduktion der mRNA der Transkriptionsfaktor-Untereinheit Fos.
Befunde zu einer Funktion von Fos, die eine Interpretation im Bezug auf den antidepressiven Effekt von Venlafaxin ermöglichen, liegen lediglich aus Tierstudien vor. Fos-ko im Hippo-kampus von Mäusen wurde mit reduziertem Angstverhalten und höherer Exzitabilität von hippokampalen Neuronen assoziiert. Auch wurde eine Assoziation mit Vorgängen bei synaptischer Plastizität und damit potentiell bei Lernvorgängen gefunden. Auf der anderen Seite wurde depressions-ähnliches Verhalten bei Ratten mit niedriger hippokampaler Fos-Expression und dessen erfolgreiche pharmakologische "Therapie" mit einer Induktion der Fos-Expression assoziiert. Es scheinen also bereits zwischen nicht-menschlichen Spezies ausgeprägte Unterschiede der Rolle von Fos beziehungsweise Fos zu bestehen.
Aufgrund der unterschiedlichen Spezies und Gewebe in den hier durchgeführten Untersuchungen sowie den uneinheitlichen Befunden bezüglich der Rolle von Fos beziehungsweise Fos in vorangegangenen Studien kann abschließend lediglich konstatiert werden, dass Fos vermutlich an der Entstehung depressionsbegünstigender Physiologie beteiligt ist und auch, dass eine antidepressive Pharmakotherapie mit Venlafaxin ihre Wirkung vermutlich unter Beteiligung von Fos entfaltet.
Die Entwicklung innovativer Antidepressiva die unter Umgehung der monoaminergen Transmissionssysteme durch gezielte Reduktion der Fos-Abundanz das therapeutische Ziel erreichen lassen, könnte auf Basis der vorliegenden Studie angedacht werden, scheint allerdings aufgrund der ubiquitären Mediatorentätigkeit des Proteins und insbesondere aufgrund seiner nicht endgültig definierten Rolle bei der Entstehung von Krebs nicht praktikabel. Zukünftige Untersuchungen sollten daher auf andere im Microarray differentiell exprimiert gefundene Gene fokussieren.
In die Untersuchung der Expressionsaktivität der für die primären Zielstrukturen von Venlafaxin (Serotonin- beziehungsweise Noradrenalin-Transporter) kodierenden Gene (SLC6A4 beziehungsweise SLC6A2) und der Serumkonzentration an aktiver Substanz nach Venlafaxin-Applikation im Hinblick auf deren Prädiktivität des therapeutischen Effektes, wurden in einem klinisch-naturalistischen Design Patienten der Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Universitätsklinikums Würzburg eingeschlossen. Genotypisiert wurden für SLC6A2 der SNP rs28386840 und für SLC6A4 der Polymorphismus 5-HTTLPR. Die Genotypen wurden jeweils in niedrig- und hoch-exprimierend unterteilt und damit auf die phänotypische Transportkapazität der präsynaptischen Membran Bezug genommen. Der therapeutische Erfolg wurde anhand der CGI-I-Skala evaluiert und für die Analysen in "gutes Ansprechen" und "schlechtes Ansprechen" dichotomisiert.
Der SLC6A2-Polymorphismus zeigte sich als nicht mit dem therapeutischen Effekt assoziiert. Der hochexprimierende SLC6A4-Genotyp wurde signifikant mit einem schlechteren Ansprechen assoziiert. Dies war in den nach Serumkonzentration aktiver Substanz stratifizierten Unterkollektiven insbesondere in dem Bereich zwischen 200 und 400 ng / ml zu erkennen, wohingegen unter- und oberhalb dieses Bereiches keine Assoziation zu finden war.
Aus diesen Resultaten kann gefolgert werden, dass sich aus der Genotypisierung von rs28386840 keine therapeutischen Instruktionen ableiten lassen. Bei Kenntnis des 5-HTTLPR-Genotyps könnte für den klinischen Alltag die Empfehlung ergehen, falls Venlafaxin als sSNRI bei Patienten mit hochexprimierendem Genotyp eingesetzt werden soll, eine Serumsummenkonzentration jenseits des durch die AGNP empfohlenen Bereiches (100 - 400 ng / ml) anzustreben.
Da hier jedoch lediglich eine Stichprobe von 56 Patienten untersucht und insbesondere, da zahlreiche potentielle Kofaktoren des therapeutischen Effektes nicht in die Analyse einbezogen werden konnten, ist die Assoziation vor Anwendung in der Therapiesteuerung anhand umfassenderer prospektiver kontrollierter Studien zu validieren.
Objective. Several neuroscience tools showed the involvement of auditory cortex in chronic tinnitus. In this proof-of-principle study we probed the capability of functional near-infrared spectroscopy (fNIRS) for the measurement of brain oxygenation in auditory cortex in dependence from chronic tinnitus and from intervention with transcranial magnetic stimulation. Methods. Twenty-three patients received continuous theta burst stimulation over the left primary auditory cortex in a randomized sham-controlled neuronavigated trial (verum = 12; placebo = 11). Before and after treatment, sound-evoked brain oxygenation in temporal areas was measured with fNIRS. Brain oxygenation was measured once in healthy controls (n = 12). Results. Sound-evoked activity in right temporal areas was increased in the patients in contrast to healthy controls. Left-sided temporal activity under the stimulated area changed over the course of the trial; high baseline oxygenation was reduced and vice versa. Conclusions. By demonstrating that rTMS interacts with auditory evoked brain activity, our results confirm earlier electrophysiological findings and indicate the sensitivity of fNIRS for detecting rTMS induced changes in brain activity. Moreover, our findings of trait-and state-related oxygenation changes indicate the potential of fNIRS for the investigation of tinnitus pathophysiology and treatment response.
Background: While most neuropathologic studies focus on regions involved in behavioral abnormalities in autism, it is also important to identify whether areas that appear functionally normal are devoid of pathologic alterations. In this study we analyzed the posteroinferior occipitotemporal gyrus, an extrastriate area not considered to be affected in autism. This area borders the fusiform gyrus, which is known to exhibit functional and cellular abnormalities in autism.
Findings: No studies have implicated posteroinferior occipitotemporal gyrus dysfunction in autism, leading us to hypothesize that neuropathology would not occur in this area. We indeed observed no significant differences in pyramidal neuron number or size in layers III, V, and VI in seven pairs of autism and controls.
Conclusions: These findings are consistent with the hypothesis that neuropathology is unique to areas involved in stereotypies and social and emotional behaviors, and support the specificity of the localization of pathology in the fusiform gyrus.
Background: Bipolar disorders (BD) are among the most severe mental disorders with first clinical signs and symptoms frequently appearing in adolescence and early adulthood. The long latency in clinical diagnosis (and subsequent adequate treatment) adversely affects the course of disease, effectiveness of interventions and health-related quality of life, and increases the economic burden of BD. Despite uncertainties about risk constellations and symptomatology in the early stages of potentially developing BD, many adolescents and young adults seek help, and most of them suffer substantially from symptoms already leading to impairments in psychosocial functioning in school, training, at work and in their social relationships. We aimed to identify subjects at risk of developing BD and investigate the efficacy and safety of early specific cognitive-behavioural psychotherapy (CBT) in this subpopulation.
Methods/Design: EarlyCBT is a randomised controlled multi-centre clinical trial to evaluate the efficacy and safety of early specific CBT, including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) versus unstructured group meetings for 14 weeks each and follow-up until week 78. Participants are recruited at seven university hospitals throughout Germany, which provide in-and outpatient care (including early recognition centres) for psychiatric patients. Subjects at high risk must be 15 to 30 years old and meet the combination of specified affective symptomatology, reduction of psychosocial functioning, and family history for (schizo) affective disorders. Primary efficacy endpoints are differences in psychosocial functioning and defined affective symptomatology at 14 weeks between groups. Secondary endpoints include the above mentioned endpoints at 7, 24, 52 and 78 weeks and the change within groups compared to baseline; perception of, reaction to and coping with stress; and conversion to full BD.
Discussion: To our knowledge, this is the first study to evaluate early specific CBT in subjects at high risk for BD. Structured diagnostic interviews are used to map the risk status and development of disease. With our study, the level of evidence for the treatment of those young patients will be significantly raised.
Background: Genomic reprogramming is thought to be, at least in part, responsible for the protective effect of brain preconditioning. Unraveling mechanisms of this endogenous neuroprotection, activated by preconditioning, is an important step towards new clinical strategies for treating asphyctic neonates. Therefore, we investigated whole-genome transcriptional changes in the brain of rats which underwent perinatal asphyxia (PA), and rats where PA was preceded by fetal asphyctic preconditioning (FAPA). Offspring were sacrificed 6 h and 96 h after birth, and whole-genome transcription was investigated using the Affymetrix Gene1.0ST chip. Microarray data were analyzed with the Bioconductor Limma package. In addition to univariate analysis, we performed Gene Set Enrichment Analysis (GSEA) in order to derive results with maximum biological relevance.
Results: We observed minimal, 25% or less, overlap of differentially regulated transcripts across different experimental groups which leads us to conclude that the transcriptional phenotype of these groups is largely unique. In both the PA and FAPA group we observe an upregulation of transcripts involved in cellular stress. Contrastingly, transcripts with a function in the cell nucleus were mostly downregulated in PA animals, while we see considerable upregulation in the FAPA group. Furthermore, we observed that histone deacetylases (HDACs) are exclusively regulated in FAPA animals.
Conclusions: This study is the first to investigate whole-genome transcription in the neonatal brain after PA alone, and after perinatal asphyxia preceded by preconditioning (FAPA). We describe several genes/pathways, such as ubiquitination and proteolysis, which were not previously linked to preconditioning-induced neuroprotection. Furthermore, we observed that the majority of upregulated genes in preconditioned animals have a function in the cell nucleus, including several epigenetic players such as HDACs, which suggests that epigenetic mechanisms are likely to play a role in preconditioning-induced neuroprotection.
Recent human and animal studies suggest that epigenetic mechanisms mediate the impact of environment on development of mental disorders. Therefore, we hypothesized that polymorphisms in epigenetic-regulatory genes impact stress-induced emotional changes. A multi-step, multi-sample gene-environment interaction analysis was conducted to test whether 31 single nucleotide polymorphisms (SNPs) in epigenetic-regulatory genes, i.e. three DNA methyltransferase genes DNMT1, DNMT3A, DNMT3B, and methylenetetrahydrofolate reductase (MTHFR), moderate emotional responses to stressful and pleasant stimuli in daily life as measured by Experience Sampling Methodology (ESM). In the first step, main and interactive effects were tested in a sample of 112 healthy individuals. Significant associations in this discovery sample were then investigated in a population-based sample of 434 individuals for replication. SNPs showing significant effects in both the discovery and replication samples were subsequently tested in three other samples of: (i) 85 unaffected siblings of patients with psychosis, (ii) 110 patients with psychotic disorders, and iii) 126 patients with a history of major depressive disorder. Multilevel linear regression analyses showed no significant association between SNPs and negative affect or positive affect. No SNPs moderated the effect of pleasant stimuli on positive affect. Three SNPs of DNMT3A (rs11683424, rs1465764, rs1465825) and 1 SNP of MTHFR (rs1801131) moderated the effect of stressful events on negative affect. Only rs11683424 of DNMT3A showed consistent directions of effect in the majority of the 5 samples. These data provide the first evidence that emotional responses to daily life stressors may be moderated by genetic variation in the genes involved in the epigenetic machinery.
Cognitive bias, the altered information processing resulting from the background emotional state of an individual, has been suggested as a promising new indicator of animal emotion. Comparable to anxious or depressed humans, animals in a putatively negative emotional state are more likely to judge an ambiguous stimulus as if it predicts a negative event, than those in positive states. The present study aimed to establish a cognitive bias test for mice based on a spatial judgment task and to apply it in a pilot study to serotonin transporter (5-HTT) knockout mice, a well-established mouse model for the study of anxiety- and depression-related behavior. In a first step, we validated that our setup can assess different expectations about the outcome of an ambiguous stimulus: mice having learned to expect something positive within a maze differed significantly in their behavior towards an unfamiliar location than animals having learned to expect something negative. In a second step, the use of spatial location as a discriminatory stimulus was confirmed by showing that mice interpret an ambiguous stimulus depending on its spatial location, with a position exactly midway between a positive and a negative reference point provoking the highest level of ambiguity. Finally, the anxiety- and depression-like phenotype of the 5-HTT knockout mouse model manifested - comparable to human conditions - in a trend for a negatively distorted interpretation of ambiguous information, albeit this effect was not statistically significant. The results suggest that the present cognitive bias test provides a useful basis to study the emotional state in mice, which may not only increase the translational value of animal models in the study of human affective disorders, but which is also a central objective of animal welfare research.
Background: Bipolar manic episodes often require hospital admission to ensure patient safety. The antipsychotic quetiapine is a common treatment for bipolar mania and is available in immediate release (IR) and extended release (XR) formulations; however, outcomes in patients receiving these different formulations have not been directly compared in an acute hospital setting.
Methods: We conducted a multinational, observational, retrospective cohort study to describe and compare hospital stay in patients admitted for an acute bipolar manic episode treated with quetiapine IR or XR from 1 October 2009-1 October 2010. The primary outcome measure was comparison of length of stay (LOS) using zero-truncated negative binomial regression.
Results: In total, 1230 patients were included (659 in the IR cohort; 571 in the XR cohort). The median LOS (interquartile range) was 18.0 days (12.0, 28.0) in the IR cohort and 20.0 days (12.0, 34.0) in the XR cohort, respectively. LOS was not significantly associated with quetiapine formulation irrespective of whether or not clinical characteristics were taken into account (p = 0.820 and p = 0.386, respectively). Overall, 84.2% and 84.4% of patients in the IR and XR cohorts, respectively, had not previously used quetiapine; of these patients, 78.7% and 68.9% received one total daily dose, and 14.4% and 23.9% received dose titration. Over half of patients received antipsychotic monotherapy (53.1% and 58.3% in the IR and XR cohorts, respectively) and most received a daily quetiapine dose >= 400 mg (64.9% and 71.8%, respectively, for quetiapine monotherapy and 59.9% and 80.3%, respectively, for combination treatment). As a secondary outcome, multivariate analysis was used to identify other factors that affect LOS. Factors associated with a longer hospital stay included public funding versus private, maximum number of new medications administered, did not receive lithium and did not receive anxiolytics, sedatives/hypnotics (all p < 0.0001). Factors associated with a shorter hospital stay included presence of drug/alcohol abuse, living accompanied and having a psychiatric medical history (all p < 0.05).
Conclusions: LOS was not found to be associated with quetiapine formulation. However, most patients received only one total daily dose of quetiapine without dose titration, which was unexpected and contrary to current recommendations.
Millions of people regularly play so-called massively multiplayer online role playing games (MMORPGs). Recently, it has been argued that MMORPG overuse is becoming a significant health problem worldwide. Symptoms such as tolerance, withdrawal, and craving have been described. Based on behavioral, resting state, and task-related neuroimaging data, we test whether frequent players of the MMORPG "World of VVarcraft" (WoW) similar to drug addicts and individuals with an increased risk for addictions show a generally deficient reward system. In frequent players of the MMORPG "World of VVarcraft" (WoW-players) and in a control group of non-gamers we assessed (1) trait sensitivity to reward (SR), (2) BOLD responses during monetary reward processing in the ventral striatum, and (3) ventral-striatal resting-state dynamics. We found a decreased neural activation in the ventral striatum during the anticipation of both small and large monetary rewards. Additionally, we show generally altered neurodynamics in this region independent of any specific task for WoW players (resting state). On the behavioral level, we found differences in trait SR, suggesting that the reward processing deficiencies found in this study are not a consequence of gaming, but predisposed to it. These findings empirically support a direct link between frequent online gaming and the broad field of behavioral and drug addiction research, thus opening new avenues for clinical interventions in addicted gamers and potentially improving the assessment of addiction-risk in the vast population of frequent gamers.
Serotonin receptor 1A gene (HTR1A) knockout mice show pronounced defensive behaviour and increased fear conditioning to ambiguous conditioned stimuli. Such behaviour is a hallmark of pathological human anxiety, as observed in panic disorder with agoraphobia (PD/AG). Thus, variations in HTR1A might contribute to neurophysiological differences within subgroups of PD/AG patients. Here, we tested this hypothesis by combining genetic with behavioural techniques and neuroimaging. In a clinical multicentre trial, patients with PD/AG received 12 sessions of manualized cognitive-behavioural therapy (CBT) and were genotyped for HTR1A rs6295. In four subsamples of this multicentre trial, exposure behaviour (n = 185), defensive reactivity measured using a behavioural avoidance test (BAT; before CBT: n = 245; after CBT: n = 171) and functional magnetic resonance imaging (fMRI) data during fear conditioning were acquired before and after CBT (n = 39). HTR1A risk genotype (GG) carriers more often escaped during the BAT before treatment. Exploratory fMRI results suggest increased activation of the amygdala in response to threat as well as safety cues before and after treatment in GG carriers. Furthermore, GG carriers demonstrated reduced effects of CBT on differential conditioning in regions including the bilateral insulae and the anterior cingulate cortex. Finally, risk genotype carriers demonstrated reduced self-initiated exposure behaviour to aversive situations. This study demonstrates the effect of HTR1A variation on defensive behaviour, amygdala activity, CBT-induced neural plasticity and normalization of defence behaviour in PD/AG. Our results, therefore, translate evidence from animal studies to humans and suggest a central role for HTR1A in differentiating subgroups of patients with anxiety disorders.
Die Aufmerksamkeitslenkung ist ein wichtiges und häufig eingesetztes Mittel zur Emotionsregulation im Alltag. Indem man den Blick vom emotionalen Fokus einer Situation ablenkt, lassen sich Emotionen effektiv reduzieren. Zum einen war das Ziel der vorliegenden Arbeit, bereits vorhandene Ergebnisse zum Einfluss emotionaler Bildstimuli auf die Early Posterior Negativity (EPN) und das Late Positive Potential (LPP) zu replizieren und weitere Beweise für den Einfluss der Aufmerksamkeitslenkung auf diese beiden Potentiale zu finden. Der Hauptfokus lag zudem darauf, zu untersuchen, ob in Abhängigkeit von subklinischer ADHS-Symptomatik die Emotionsregulation durch Aufmerksamkeitslenkung beeinträchtigt ist.
Als Stichprobe wurden 53 Erwachsene zwischen 18 und 40 Jahren herangezogen. Ihnen wurden 80 positive, 80 negative und 40 neutrale Bilder aus dem International Affective Picture System (Lang et al., 1999) und einer Studie von Schienle und Kollegen (2001) präsentiert - entweder mit der Anweisung, einen emotionalen Punkt oder einen neutralen Bildteil zu betrachten. Während der Präsentation erfolgte die Aufzeichnung der EEG Daten.
Wir konnten weitere Belege erbringen, dass sowohl die EPN wie auch das LPP sensitive Marker für die frühe selektive Aufmerksamkeit und gesteigerte Verarbeitung emotionaler Bildreize sind. Auch für den Einfluss der Aufmerksamkeitslenkung auf das LPP konnte ein weiterer Beleg erbracht werden. Außerdem fanden sich Hinweise auf eine verschlechterte Fähigkeit zur Emotionsregulation bei negativen Bildreizen in Abhängigkeit von steigender AHDS Symptomatik .
The extinction of conditioned fear depends on an efficient interplay between the amygdala and the medial prefrontal cortex (mPFC). In rats, high-frequency electrical mPFC stimulation has been shown to improve extinction by means of a reduction of amygdala activity. However, so far it is unclear whether stimulation of homologues regions in humans might have similar beneficial effects. Healthy volunteers received one session of either active or sham repetitive transcranial magnetic stimulation (rTMS) covering the mPFC while undergoing a 2-day fear conditioning and extinction paradigm. Repetitive TMS was applied offline after fear acquisition in which one of two faces (CS+ but not CS−) was associated with an aversive scream (UCS). Immediate extinction learning (day 1) and extinction recall (day 2) were conducted without UCS delivery. Conditioned responses (CR) were assessed in a multimodal approach using fear-potentiated startle (FPS), skin conductance responses (SCR), functional near-infrared spectroscopy (fNIRS), and self-report scales. Consistent with the hypothesis of a modulated processing of conditioned fear after high-frequency rTMS, the active group showed a reduced CS+/CS− discrimination during extinction learning as evident in FPS as well as in SCR and arousal ratings. FPS responses to CS+ further showed a linear decrement throughout both extinction sessions. This study describes the first experimental approach of influencing conditioned fear by using rTMS and can thus be a basis for future studies investigating a complementation of mPFC stimulation to cognitive behavioral therapy (CBT).
Predominant polarity in bipolar disorder and validation of the polarity index in a German sample
(2014)
Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339–346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample.
Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP.
Results: In our sample, 63.9% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics.
However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment.
Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment.
Die Demenz vom Alzheimer Typ ist eine primär degenerative Erkrankung des Gehirns, die heutzutage die häufigste Ursache für eine Demenzerkrankung darstellt. Sie ist pathologisch gekennzeichnet durch typische histologische fassbare zerebrale Veränderungen, Neurofibrillenbündel und amyloide Plaques, und einer ausgeprägten, kortikal betonten Hirnatrophie gekennzeichnet. Zu den wichtigsten klinischen Leitsymptomen zählen Gedächtnis- und Wortfindungsstörungen sowie eine zeitliche und örtliche Orientierungsstörung. Es werden zwei Formen unterschieden: Die seltene familiär autosomal- dominant vererbte Form mit frühem Beginn (Beginn vor dem 65. Lebensjahr) und die häufigste, die sporadische Form (Beginn nach dem 65. Lebensjahr), deren Ursache bis heute nicht vollständig geklärt ist.
Zu den wichtigsten Risikofaktoren der sAD zählt neben einer positiven Familienanamnese vor allem das Alter. Mittlerweile konnten immer mehr Studien auch ein deutlich hohes Risiko für AD besonders für Patienten mit unbehandelter Hypertonie belegen. Inzwischen mehren sich seit längerer Zeit die Hinweise, dass ein wichtiger Zusammenhang zwischen der Entstehung von sAD und arterieller Hypertonie besteht.
Ausgehend von der Hypothese, dass ein gestörter zerebraler Insulinmetabolismus pathogenetisch bedeutsam für die Entwicklung einer sAD ist, werden in der Literatur zudem gehirnspezifische Veränderungen in der Insulin/ IR-Signalkaskade bei sAD beschrieben, die daraufhin deuten, dass es sich bei sAD um eine neuroendokrine Störung handelt.
Die vorliegende Studie beschäftigt sich nun mit der Frage, ob ein Zusammenhang zwischen metabolischen Syndrom (wie arterielle Hypertonie und Insulinresistenz) und sAD nachweisbar ist und ob Hypertonie gehirnspezifische Veränderungen in der in der Insulin/ IR-Signalkaskade hervorrufen und somit auf diesen Weg pathophysiologischen Prozesse einer sAD fördern kann.
Um diesen Zusammenhang zu überprüfen, wurden in dieser Studie erstmals Spontan Hypertensive Ratten (SHR) als experimentelles Modell ausgewählt. Dabei wurden Veränderungen bezüglich der Insulinrezeptorkonzentration sowie weiterer Bestandteile der Insulin/ IR-Signalkaskade in Gehirnen von drei Monate alten SHR und altersentsprechenden Kontrollratten mittels Enzym- Linked-Immuno-Sorbent Assays (ELISA) untersucht und miteinander verglichen.
In dieser Studie war sowohl insgesamt als auch in allen untersuchten Regionen mit Ausnahme des Hypothalamus eine Erniedrigung der IRβ - Konzentration und damit ein deutlicher Mangel an IR β im Hirngewebe der SHR nachweisbar. Die Resultate des IR pTyr –fielen mit einer insgesamt tendenziellen Reduktion der IR pTyr – Konzentration der SHR ähnlich aus, wobei es innerhalb der Hirnregionen regionale Konzentrationsunterschiede gab. Bezüglich der aktivierten PKB ergab sich eine erniedrigte Gesamtkonzentration im Hirngewebe der SHR, allerdings war beim Gruppenvergleich in den einzelnen Hirnregionen nur im Hippokampus ein eindeutig signifikanter Konzentrationsunterschied zwischen beiden Gruppen zu verzeichnen. Die GSK 3β - Gesamtkonzentration der SHR zeigte sowohl insgesamt als auch in Vergleich zur Kontrollgruppe eine deutliche Erniedrigung. Im Gegensatz hierzu war die GSK- 3β pSer- Gesamtkonzentrationen der SHR insgesamt leicht erniedrigt, beim Vergleich der vier verschiedenen Hirnregionen zeigten sich jedoch keine signifikanten regionalen Konzentrationsunterschiede.
Ein eindeutiger statistischer Zusammenhang zwischen den Nüchtern- Blutzuckerspiegel, den Blutzuckerspiegel 30 Minuten nach Glukosetoleranztest und den jeweiligen Körpergewicht der SHR und den Bestandteilen der Insulinrezeptorsignalkaskade konnte in der vorliegenden Studie nicht beobachtet werden.
Zusammenfassend lässt sich sagen, dass in den Gesamtproben der SHR signifikante Störungen in der Signaltransduktion des Insulin-/ Insulinrezeptorsystem nachgewiesen werden konnten, die in der Literatur für sAD als typisch beschrieben werden.
Dies untermauert wiederum die Hypothese, dass es sich bei der sAD um eine neuroendokrine Störung mit gehirnspezifischen Fehlfunktionen in der Insulinrezeptorsignalkaskade handelt. Des Weiteren lässt diese Arbeit den Schluss zu, dass es einen möglichen Zusammenhang zwischen metabolischem Syndrom (wie arterielle Hypertonie und Insulinresistenz) und sAD gibt und Hypertonie ein bedeutsamer Risikofaktor für die Entwicklung einer sAD sein kann. Eine direkte Verbindung zwischen beiden Erkrankungen konnte jedoch nicht nachgewiesen werden.
Weiterführende und ergänzende Untersuchungen mit zum Beispiel älteren SHR und zusätzlichen histopathologsichen Untersuchung werden jedoch notwendig sein, um diese Aussage zu bestätigen.
Das Enzym Catechol-O- Methyltransferase (COMT) spielt eine wichtige Rolle beim Abbau der Neurotransmitter Dopamin, Noradrenalin und Adrenalin. In dessen Gen befindet sich ein Polymorphismus (SNP), der einen Aminosäureaustausch von Valin zu Methionin an Position 158 der membrangebundenden Isoform bewirkt.. In früheren Studien zeigen die verschiedenen Genotypen des Polymorphismus Unterschiede in der emotionalen Verarbeitung, bei der die COMT Einfluss auf die Verarbeitung von negativen, aber nicht von positiven Stimuli zeigt. Neben emotionalen werden durch die COMT aber auch kognitive präfrontale Prozesse beeinflusst. Eine Aufmerksamkeitslenkung auf Bilder führt im Zeitfenster der EPN und LPP zu ähnlichen Effekten wie beim Betrachten emotionaler Bilder In dieser Studie sollte daher untersucht werden, ob die COMT- Effekte auf die Emotionsverarbeitung durch Aufmerksamkeitsprozesse begründet sind und diese unabhängig vom emotionalen Inhalt durch die Aufmerksamkeitsinstruktion auslösbar sind.
Dafür wurden bei 48 gesunden und entweder Val/Val oder Met/Met- Homozygoten Probanden während der Präsentation von IAPS Bildern mit positiven, negativen und neutralen Bildern ein EEG abgeleitet. Und es wurde die neuronale Aktivierung bei emotionalen Stimuli, in Interaktion mit der Instruktion, die Aufmerksamkeit auf eine bestimmte emotionale Kategorie zu richten, untersucht. Dabei zeigten sich die erwarteten Emotions- und Aufmerksamkeitseffekte auf EPN und LPP. Keinen Einfluss hatte der COMT-Genotyp. Dies könnte an der Interferenz der Emotionseffekte mit kognitiven Effekten des COMT- Polymorphismus liegen.
Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls
(2014)
Background
Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization.
Methods
We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression.
Results
All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups.
Conclusions
Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS.